ArcherDx will develop in vitro diagnostic tests, including companion diagnostics, to run on Illumina's NextSeq 550Dx next-generation sequencing system.
Researchers saw signs of an unreported Zika virus outbreak in Cuba in 2017, well after the documented decline in new cases in Brazil and other parts of the world.
The FLASH method, which depletes unwanted DNA from samples, allows labs to perform deep metagenomic sequencing on smaller, less expensive instruments.
The projects, set to begin this year, concern prostate cancer, infectious diseases, rheumatoid arthritis, inflammatory bowel disease, heart disease, and sleep disorders.
CareDx claims that Natera is infringing on two of its patents related to non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.
ArcherDX plans to keep its research and development efforts in its current facility and move its clinical and commercial testing operations to Baby Gene's CLIA lab.
The firm's assay measures the concentration of the wild type and mutant alleles of hFE protein at three different mutation sites from a person's blood sample.
Simulated population data suggests that the lifetime risk of cervical cancer is lower for women who stop screening after a negative DNA test for oncogenic HPV.
At AMP, the companies announced a partnership to add Paragon Genomics' NGS target enrichment technologies to the flagship Sophia AI platform worldwide.
The test is intended to identify patients with ROS1, NTRK, and ALK gene fusions for treatment with TP's investigational drug repotrectinib.
The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.
60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.
In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.
GenomeWeb reports that Veritas Genetics is suspending its US operations.